Key result
Cyclovirobuxine D pretreatment attenuated doxorubicin-induced cardiomyopathy by suppressing oxidative damage and mitochondrial biogenesis impairment.
Why the study?
Does Cyclovirobuxine D pretreatment prevent doxorubicin-induced cardiomyopathy in preclinical models?
Population
Preclinical model of doxorubicin-induced cardiomyopathy (myocardial cells)
Comparison
Cyclovirobuxine D (CVB-D) pretreatment vs Doxorubicin without CVB-D pretreatment
Design
Preclinical
Authors
Loading...
May protect against doxorubicin cardiomyopathy in animals; hypothesis-generating and requires clinical trials before any practice change.
Does Cyclovirobuxine D pretreatment prevent doxorubicin-induced cardiomyopathy in preclinical models?
Cyclovirobuxine D protects against doxorubicin-induced cardiomyopathy by suppressing oxidative damage and preserving mitochondrial biogenesis in preclinical models.
Guo et al. (2015) studied Doxorubicin-induced cardiomyopathy. Cyclovirobuxine D (CVB-D) vs. Doxorubicin alone was evaluated on Cardiac contractile dysfunction and histological alterations. Cyclovirobuxine D pretreatment attenuated doxorubicin-induced cardiomyopathy by suppressing oxidative damage and mitochondrial biogenesis impairment.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: